Manufactures pharmaceutical-grade mineral compounds (calcium, magnesium, zinc salts) used as excipients and nutraceutical ingredients.
Manufactures pharmaceutical-grade mineral compounds (calcium, magnesium, zinc salts) used as excipients and nutraceutical ingredients.
In one line: A niche pharma-grade mineral excipient maker.
Moat: narrow (process know-how, regulatory licence). Pharma-grade quality certifications for mineral excipients create a technical barrier versus commodity suppliers.
Headquarters: Gujarat, India · Employees: 651
Size Sudeep Pharma (SUDEEPPHRM.NS) is an India Health Care company (Pharmaceuticals: Other) with a market value of $1.45B, the 488th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,202 on 18 Nov 2026.
Performance Over six months the shares gained 85.3%, against -8.1% for the median peer and +3.8% for the India market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 26.8% over the last twelve months (peer median +9.3%); the operating margin is 32.9% (peer median 15.1%).
Valuation It trades at 69.1× forward earnings against a peer median of 16.2× (2nd most expensive of 18).
Capital Return on invested capital runs 2.7 points above its cost of capital (13.7% WACC).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹7.10B | ₹6.39B | ₹4.97B | ₹4.55B | ₹4.26B |
| Revenue growth | — | +28% | +9% | +7% | — |
| Gross profit | ₹3.87B | ₹3.17B | ₹2.57B | ₹2.25B | ₹1.44B |
| EBITDA | ₹2.51B | ₹2.31B | ₹1.90B | ₹1.80B | ₹886M |
| Net income | ₹1.88B | ₹1.73B | ₹1.39B | ₹1.33B | ₹623M |
| Free cash flow | n/a | -₹566M | -₹208M | ₹95.9M | -₹33.1M |
| Capital expenditure | n/a | ₹1.18B | ₹642M | ₹525M | ₹472M |
| Total debt | ₹1.89B | ₹1.50B | ₹1.38B | ₹787M | ₹831M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SUDEEPPHRM.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +19.8% | -2.3% | 3rd highest of 21 |
| 6-month return | +85.3% | -8.1% | 2nd highest of 21 |
| Distance from 52-week high | -12.8% | -29.7% | 5th highest of 21 |
| Revenue growth (TTM) | +26.8% | +9.3% | 6th highest of 21 |
| Operating margin | 32.9% | 15.1% | 2nd highest of 21 |
| Forward P/E | 69.1× | 16.2× | 2nd most expensive of 18 |
| ROIC minus cost of capital | +2.7 pp | +4.0 pp | 11th highest of 21 |
| EV / EBITDA | 54.5× | 17.3× | most expensive of 12 |
| Net debt / EBITDA | 0.3× | -0.3× | 4th most indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sudeep Pharma SUDEEPPHRM.NS | India | $1.45B | +85% | +27% | 33% | 69.1× | n/a | n/a |
| Zhejiang Medicine 600216.SS | China | $1.51B | -26% | -6% | 7% | 11.5× | -7.8% | +3.9% |
| Tibet Cheezheng Tibetan Medicine 002287.SZ | China | $1.58B | -17% | -7% | 28% | n/a | -1.9% | +10.4% |
| Jamieson Wellness JWEL.TO | Canada | $1.32B | +32% | +12% | 13% | 20.6× | 13.5% | +15.3% |
| Porton Pharma Solutions 300363.SZ | China | $1.66B | +37% | +6% | -2% | n/a | 2.1% | +10.4% |
| Bora Pharmaceuticals 6472.TW | Taiwan | $1.25B | -2% | +7% | 14% | 10.8× | 3.5% | +60.2% |
| BioGaia BIOG-B.ST | Sweden | $1.25B | -4% | +13% | 28% | 31.0× | 1.5% | +15.5% |
| Pharma Mar PHM.MC | Spain | $1.21B | -38% | +32% | 19% | 41.4× | 10.6% | -3.9% |
| Cronos CRON.TO | Canada | $1.17B | +24% | +55% | 5% | 16.2× | 18.8% | +26.7% |
| HBM 2142.HK | Hong Kong | $1.12B | -18% | +55% | 44% | 11.7× | 13.1% | +62.3% |
| China Meheco 600056.SS | China | $1.90B | -16% | +2% | 3% | n/a | -1.3% | -2.1% |
| Guilin Sanjin Pharmaceutical 002275.SZ | China | $1.05B | -12% | -3% | 24% | 12.8× | -8.7% | +5.5% |
| Shandong Xinhua Pharmaceutical 0719.HK | Hong Kong | $1.03B | -19% | -1% | 4% | 6.2× | -2.1% | +7.1% |
| Granules India GRANULES.NS | India | $2.12B | +4% | +22% | 17% | 24.8× | 23.6% | +10.6% |
| Applied Nutrition APN.L | United Kingdom | $986M | +31% | +51% | 25% | 21.4× | 24.6% | +38.5% |
| Health and Happiness (H&H) International 1112.HK | Hong Kong | $2.15B | +108% | +24% | 16% | 13.2× | -1.7% | +4.4% |
| New Journey Health Technology Group Co., Ltd.Class A 002219.SZ | China | $942M | -18% | -14% | 8% | 182.0× | n/a | n/a |
| China Resources Jiangzhong Pharmaceutical 600750.SS | China | $2.27B | +4% | -10% | 24% | 16.5× | -1.9% | +11.6% |
| PharmaNutra PHN.MI | Italy | $922M | +2% | +17% | 22% | 33.5× | 4.7% | +18.5% |
| China Resources Double-Crane Pharmaceutical 600062.SS | China | $2.35B | -14% | -1% | 13% | 9.3× | -9.1% | +5.3% |
| Sihuan Pharmaceutical 0460.HK | Hong Kong | $856M | -34% | +30% | 15% | 8.7× | n/a | n/a |